Search

Your search keyword '"Sato, Satoshi"' showing total 45 results
Start Over Author "Sato, Satoshi" Publisher wiley
45 results on '"Sato, Satoshi"'

1. Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study

Author

Okuyama, Yoshiharu, primary, Hatakeyama, Shingo, additional, Tabata, Ryuji, additional, Fujimori, Daiji, additional, Kawashima, Yohei, additional, Tanaka, Toshikazu, additional, Fujita, Naoki, additional, Okamoto, Teppei, additional, Mori, Kazuyuki, additional, Yamamoto, Hayato, additional, Yoneyama, Takahiro, additional, Hashimoto, Yasuhiro, additional, Matsuoka, Toshimitsu, additional, Sato, Satoshi, additional, and Ohyama, Chikara, additional

Published
2023
Full Text
View/download PDF

6. P‐138: Rollable Multi‐Touch Organic Capacitive Pressure Sensor for Multi‐Directional User Interactions

Author

Ebisui, Akira, primary, Kaneko, Hiroki, additional, Tsukamoto, Kei, additional, Harada, Tomoko, additional, Goto, Tetsuro, additional, Sakakura, Yoshiaki, additional, Miyawaki, Manami, additional, Hasegawa, Hayato, additional, Kobayashi, Ken, additional, Sato, Satoshi, additional, Kamei, Takahiro, additional, and Nomoto, Kazumasa, additional

Published
2019
Full Text
View/download PDF

44. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.

Author

Miyamoto T, Izawa K, Masui S, Yamazaki A, Yamasaki Y, Matsubayashi T, Shiraki M, Ohnishi H, Yasumura J, Kawabe T, Miyamae T, Matsubara T, Arakawa N, Ishige T, Takizawa T, Shimbo A, Shimizu M, Kimura N, Maeda Y, Maruyama Y, Shigemura T, Furuta J, Sato S, Tanaka H, Izumikawa M, Yamamura M, Hasegawa T, Kaneko H, Nakagishi Y, Nakano N, Iida Y, Nakamura T, Wakiguchi H, Hoshina T, Kawai T, Murakami K, Akizuki S, Morinobu A, Ohmura K, Eguchi K, Sonoda M, Ishimura M, Furuno K, Kashiwado M, Mori M, Kawahata K, Hayama K, Shimoyama K, Sasaki N, Ito T, Umebayashi H, Omori T, Nakamichi S, Dohmoto T, Hasegawa Y, Kawashima H, Watanabe S, Taguchi Y, Nakaseko H, Iwata N, Kohno H, Ando T, Ito Y, Kataoka Y, Saeki T, Kaneko U, Murase A, Hattori S, Nozawa T, Nishimura K, Nakano R, Watanabe M, Yashiro M, Nakamura T, Komai T, Kato K, Honda Y, Hiejima E, Yonezawa A, Bessho K, Okada S, Ohara O, Takita J, Yasumi T, and Nishikomori R

Subjects
Humans, Japan, Female, Male, Retrospective Studies, Child, Child, Preschool, Adult, Adolescent, Young Adult, Treatment Outcome, Middle Aged, Infant, NLR Family, Pyrin Domain-Containing 3 Protein genetics, Mutation, Remission Induction, Cryopyrin-Associated Periodic Syndromes drug therapy, Cryopyrin-Associated Periodic Syndromes genetics, Antibodies, Monoclonal, Humanized therapeutic use
Abstract

Objective: We assess the clinical characteristics of patients with cryopyrin-associated periodic syndrome (CAPS) in Japan and evaluate the real-world efficacy and safety of interleukin-1 (IL-1) inhibitors, primarily canakinumab., Methods: Clinical information was collected retrospectively, and serum concentrations of canakinumab and cytokines were analyzed., Results: A total of 101 patients were included, with 86 and 15 carrying heterozygous germline and somatic mosaic mutations, respectively. We identified 39 mutation types, and the common CAPS-associated symptoms corresponded with those in previous reports. Six patients (5.9% of all patients) died, with four of the deaths caused by CAPS-associated symptoms. Notably, 73.7% of patients (100%, 79.6%, and 44.4% of familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and chronic infantile neurological cutaneous articular syndrome/neonatal onset multisystem inflammatory disease, respectively) achieved complete remission with canakinumab, and early therapeutic intervention was associated with better auditory outcomes. In some patients, canakinumab treatment stabilized the progression of epiphysial overgrowth and improved height gain, visual acuity, and renal function. However, 23.7% of patients did not achieve inflammatory remission with crucial deterioration of organ damage, with two dying while receiving high-dose canakinumab treatment. Serological analysis of canakinumab and cytokine concentrations revealed that the poor response was not related to canakinumab shortage. Four inflammatory nonremitters developed inflammatory bowel disease (IBD)-unclassified during canakinumab treatment. Dual biologic therapy with canakinumab and anti-tumor necrosis factor-α agents was effective for IBD- and CAPS-associated symptoms not resolved by canakinumab monotherapy., Conclusion: This study provides one of the largest epidemiologic data sets for CAPS. Although early initiation of anti-IL-1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS after canakinumab treatment., (© 2024 American College of Rheumatology.)

Published
2024
Full Text
View/download PDF

45. Gangliosides and beta1-integrin are required for caveolae and membrane domains.

Author

Singh RD, Marks DL, Holicky EL, Wheatley CL, Kaptzan T, Sato SB, Kobayashi T, Ling K, and Pagano RE

Subjects
Caveolin 1 metabolism, Endocytosis, Focal Adhesion Protein-Tyrosine Kinases metabolism, Glycoside Hydrolases pharmacology, Humans, Membrane Microdomains metabolism, Neuraminidase pharmacology, Paxillin metabolism, Talin metabolism, Caveolae metabolism, Fibroblasts metabolism, Gangliosides metabolism, Integrin beta1 metabolism, Skin metabolism
Abstract

Caveolae are plasma membrane domains involved in the uptake of certain pathogens and toxins. Internalization of some cell surface integrins occurs via caveolae suggesting caveolae may play a crucial role in modulating integrin-mediated adhesion and cell migration. Here we demonstrate a critical role for gangliosides (sialo-glycosphingolipids) in regulating caveolar endocytosis in human skin fibroblasts. Pretreatment of cells with endoglycoceramidase (cleaves glycosphingolipids) or sialidase (modifies cell surface gangliosides and glycoproteins) selectively inhibited caveolar endocytosis by >70%, inhibited the formation of plasma membrane domains enriched in sphingolipids and cholesterol ('lipid rafts'), reduced caveolae and caveolin-1 at the plasma membrane by approximately 80%, and blunted activation of beta1-integrin, a protein required for caveolar endocytosis in these cells. These effects could be reversed by a brief incubation with gangliosides (but not with asialo-gangliosides or other sphingolipids) at 10 degrees C, suggesting that sialo-lipids are critical in supporting caveolar endocytosis. Endoglycoceramidase treatment also caused a redistribution of focal adhesion kinase, paxillin, talin, and PIP Kinase Igamma away from focal adhesions. The effects of sialidase or endoglycoceramidase on membrane domains and the distribution of caveolin-1 could be recapitulated by beta1-integrin knockdown. These results suggest that both gangliosides and beta1-integrin are required for maintenance of caveolae and plasma membrane domains.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results